RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.

A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.

Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”

Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.